NASDAQ:CYTO Altamira Therapeutics (CYTO) Stock Price, News & Analysis $0.48 0.00 (-0.79%) (As of 03:30 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Altamira Therapeutics Stock (NASDAQ:CYTO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Altamira Therapeutics alerts:Sign Up Key Stats Today's Range$0.47▼$0.5050-Day Range$0.48▼$0.9652-Week Range$0.45▼$17.20Volume13,779 shsAverage Volume776,715 shsMarket Capitalization$1.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAltamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Read More… America dodged a crisis — next time it could be much worse (Ad)Legendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.Click here and follow the three simple steps Martin shares in this video to protect your savings whi Altamira Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks34th Percentile Overall ScoreCYTO MarketRank™: Altamira Therapeutics scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Altamira Therapeutics.Read more about Altamira Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Altamira Therapeutics are expected to grow in the coming year, from ($2.65) to ($1.17) per share.Price to Book Value per Share RatioAltamira Therapeutics has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.31% of the float of Altamira Therapeutics has been sold short.Short Interest Ratio / Days to CoverAltamira Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Altamira Therapeutics has recently decreased by 50.85%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAltamira Therapeutics does not currently pay a dividend.Dividend GrowthAltamira Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.31% of the float of Altamira Therapeutics has been sold short.Short Interest Ratio / Days to CoverAltamira Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Altamira Therapeutics has recently decreased by 50.85%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News SentimentN/A News SentimentAltamira Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Altamira Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.03% of the stock of Altamira Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.91% of the stock of Altamira Therapeutics is held by institutions.Read more about Altamira Therapeutics' insider trading history. Receive CYTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTO Stock News HeadlinesAltamira Therapeutics Provides Update on Nasdaq ListingOctober 4, 2024 | globenewswire.comAltamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal SpraySeptember 27, 2024 | globenewswire.com2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running.November 1, 2024 | Investing Daily (Ad)Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Earnings Call TranscriptSeptember 26, 2024 | msn.comAltamira Therapeutics Ltd (CYTO) Q2 2024 Earnings Call Transcript Highlights: Key Financial and ...September 25, 2024 | finance.yahoo.comAltamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call TranscriptSeptember 24, 2024 | seekingalpha.comAltamira Therapeutics Provides Business Update and First Half 2024 Financial ResultsSeptember 24, 2024 | globenewswire.comNuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East AsiaSeptember 23, 2024 | finance.yahoo.comSee More Headlines CYTO Stock Analysis - Frequently Asked Questions How have CYTO shares performed this year? Altamira Therapeutics' stock was trading at $3.48 at the beginning of the year. Since then, CYTO stock has decreased by 85.7% and is now trading at $0.4981. View the best growth stocks for 2024 here. When did Altamira Therapeutics' stock split? Shares of Altamira Therapeutics reverse split on the morning of Wednesday, December 13th 2023. The 1-20 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Altamira Therapeutics? Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Altamira Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Altamira Therapeutics investors own include Plug Power (PLUG), Aridis Pharmaceuticals (ARDS), Soligenix (SNGX), Chemomab Therapeutics (CMMB), CNS Pharmaceuticals (CNSP), Cara Therapeutics (CARA) and Draganfly (DPRO). Company Calendar Today11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYTO CUSIPN/A CIK1601936 Webwww.aurismedical.com Phone(441) 295-5950Fax41-61-201-1351Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick RatioN/A Sales & Book Value Annual Sales$320,000.00 Price / Sales5.14 Cash FlowN/A Price / Cash FlowN/A Book Value$4.56 per share Price / Book0.11Miscellaneous Outstanding Shares3,401,000Free Float2,958,000Market Cap$1.65 million OptionableNot Optionable Beta1.79 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CYTO) was last updated on 11/1/2024 by MarketBeat.com Staff From Our PartnersEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredCapitalize on Generational Opportunities in the ‘Roaring 2020s’The industrial revolutions in our country's past have connected the world in ways never thought possible… C...Unstoppable Prosperity | SponsoredIf You’re Even Thinking of Investing in AI, Read This First.If you're starting to invest in AI or even just thinking about it, it can feel overwhelming and even a bit sca...Brownstone Research | Sponsored4 Trades for $4?! (Next Pick Goes LIVE Tues!)Bryan wants show you his unique trading philosophy... It allows his members to take profits early again and...Monument Traders Alliance | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altamira Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.